Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma
- 1 September 2010
- journal article
- Published by Elsevier in Laboratory Investigation
- Vol. 90 (9) , 1346-1356
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancerMolecular Cancer, 2009
- Bortezomib (Velcade) Induces p27Kip1 Expression through S-Phase Kinase Protein 2 Degradation in Colorectal CancerCancer Research, 2008
- Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern populationOncogene, 2008
- Sanguinarine-Dependent Induction of Apoptosis in Primary Effusion Lymphoma CellsCancer Research, 2007
- Inhibition of c-Met as a Therapeutic Strategy for Esophageal AdenocarcinomaNeoplasia, 2006
- Prevalence of Fragile Histidine Triad Expression in Tumors from Saudi Arabia: A Tissue Microarray AnalysisCancer Epidemiology, Biomarkers & Prevention, 2006
- Inhibition of Phosphatidylinositol 3′-Kinase/AKT Signaling Promotes Apoptosis of Primary Effusion Lymphoma CellsClinical Cancer Research, 2005
- Prognostic significance of hepatocyte growth factor and c‐MET expression in patients with diffuse large B‐cell lymphomaBritish Journal of Haematology, 2004
- Inhibition of phosphatidylinositol 3′-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathwayBiochemical and Biophysical Research Communications, 2004
- c‐met tyrosine kinase receptor expression is associated with abnormal β‐catenin expression and favourable prognostic factors in invasive breast carcinomaHistopathology, 2000